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Abstract Multi-attribute utility-based instruments
(MAUIs) assess health status and provide an index score on
the full health-dead scale, and are widely used to support
reimbursement decisions for new healthcare interventions
worldwide. A valuation study is a key part of the devel-
opment of MAUIs, with the primary goal of developing a
scoring algorithm through eliciting societal preferences.
We developed the 21-item Checklist for REporting
VAluaTion StudiEs (CREATE) by following a modified
two-round Delphi panel approach plus an email survey.
CREATE is intended to promote good reporting practice as
well as guiding developers to thoroughly and carefully
think through key methodological elements in designing
valuation studies.
Key Points
Good reporting standards assist developers and users
in critically appraising studies and improving the
reproducibility of published results.
The development of value sets for multi-attribute
utility instruments (MAUIs) has proliferated in
recent years, with many countries seeking to support
local reimbursement decision making with their own
societal preference-based valuation studies.
Guidance is lacking on the key components that
should be reported in a valuation study.
This study describes the key elements that should be
reported for valuation studies of MAUIs—the
Checklist for REporting VAluaTion StudiEs
(CREATE).
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Multi-attribute utility-based instruments (MAUIs) assess
health status, typically with a small number of questions that
describe health, and facilitate the ability to generate a pref-
erence-based summary score (i.e. value or utility, anchored
at zero for dead and one for full health, hereafter collectively
referred to as ‘index value’) for each health state the MAUI
defines. The development of an MAUI involves two major
steps: the development of a descriptive system (i.e. health-
state classification), followed by a valuation study in which
the preference weights are obtained from a representative
sample of the general population. The latter typically in-
volves elicitation of preferences for a subset of health states
that are described by the MAUI from each respondent, fol-
lowed by estimation of a scoring algorithm that allows for the
generation of an index value for every health state described
by the MAUI (i.e. the value set).
These index values are applied in economic evaluations
of healthcare interventions to calculate quality-adjusted
life-years (QALYs). A few established MAUIs include the
Health Utilities Index [1, 2], the Short-Form (SF)-6D [3],
the EQ-5D [4, 5], and the Assessment of Quality of Life
(AQoL)-8D [6].
While only a handful of MAUIs are prominent in the
literature, many country-specific valuation studies have
been conducted for most of these MAUIs as health tech-
nology assessment guidelines often suggest local societal
preferences be applied to economic evaluations of health-
care interventions to inform resource allocation decision
making [7–10]. A valuation study of an MAUI is aimed at
developing a scoring algorithm that assigns values to all
possible health states for that instrument. Conducting a
valuation study is methodologically challenging, time
consuming, and resource intensive. However, once a value
set is developed, MAUIs are relatively easy to administer
and score, and have the advantage of providing comparable
valuations across different diseases and interventions. Fur-
thermore, as MAUIs impose modest respondent burden
relative to psychometrically-derived measures of health that
typically contain multi-scale and multi-item for each scale,
MAUIs are increasingly used for a variety of purposes be-
yond economic evaluations. They provide a profile and
single summary score, a succinct indicator of health-related
quality of life (HRQL) that can be employed in a clinical
context or for monitoring population health [11–14].
A valuation study involves many considerations, re-
quiring thoughtful planning around its design, implemen-
tation, and analysis. Many options for eliciting and
modeling valuation data are available, and methods are still
under development, for which there is no gold standard that
is accepted unanimously by the scientific community.
Rather, it is important for peer reviewers and potential
users of these value sets to be able to identify and critically
appraise more important aspects of study design and
methods that can affect the resulting valuations and, ulti-
mately, whether the values provide a defensible and valid
basis for healthcare decision making. Thus, it is important
that all relevant details should be disclosed in a manuscript
by the authors/developers of value sets. Upon reporting key
elements to the informed user, the potential user can then
determine whether the value set is of sufficient method-
ological quality and well-suited to the intended use. A re-
cent review of EQ-5D valuation studies revealed that the
reporting quality varied across studies, and highlighted the
potential value of a checklist or guidelines to assist de-
velopers in reporting valuation studies of MAUIs, and
users to assess them [15]. Therefore, our objective was to
develop a checklist for valuation studies of MAUIs, the
Checklist for REporting VAluaTion StudiEs (CREATE).
2 Methods
2.1 Checklist for REporting VAluaTion StudiEs
(CREATE) Expert Panel
The development of CREATE was initiated by Feng Xie
and A. Simon Pickard, who then enlisted an expert panel to
provide inputs and guidance on the checklist. The panel
consisted of five members: Dr. Nancy Devlin, Office of
Health Economics, UK; Dr. Paul Krabbe, University of
Groningen, The Netherlands; Dr. Rosalie Viney, Univer-
sity of Technology Sydney, Australia; Dr. Dennis Revicki,
Evidera Inc., US; and Dr. David Feeny, Department of
Economics, McMaster University, Canada. Members of the
panel were selected based on their longstanding academic
expertise in health utility measurement and HRQL re-
search, and in the estimation of multi-attribute utility
functions. This panel consists of a diverse group of scien-
tists who have an interest in health preference-based re-
search and have conducted extensive research on existing
MAUIs such as the EQ-5D, SF-6D, Health Utilities Index
(HUI), Quality of Well-Being, and AQoL.
2.2 CREATE Development
We followed the international reporting guideline devel-
opment framework [16], where a review was conducted to
identify any published reporting guidelines related to
MAUI valuation studies in general. No such guideline was
identified in the public domain. A list of 35 items was
initially compiled based on a systematic literature review
of EQ-5D valuation studies [15]. Although that list was
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specifically developed for the EQ-5D valuation studies,
many of those items were applicable to other MAUIs, with
a simple rephrase. In addition, major themes that repre-
sented components of the development of value sets were
identified to organize the items.
We adopted a modified Delphi panel approach, asking
the expert panel via email to independently assess the
content validity, completeness, and wording of these 35
items, and suggest any additional items if needed. Upon
receiving input from the expert panel, items were refined
and several items dropped, resulting in a checklist of 26
items. Inputs on the 26 candidate items were solicited from
members of the EuroQol Research Foundation through an
email survey, and a deliberation took place while review-
ing all the responses. Members of the EuroQol Research
Foundation include developers of the EQ-5D, SF-6D, and
15D. The Group is comprised of approximately 70 re-
searchers from across the globe whose research interests
include health utility measurement, many of whom have
conducted studies related to value set development. Each
participant was asked to assess how important each item
was, as included in a reporting checklist for valuation
studies, by indicating it as ‘required’ (defined as essential
to understand and evaluate the methodological rigor of the
study), ‘recommended’ (defined as helpful to understand
and evaluate the rigor), or ‘optional’ (defined as not nec-
essary/applicable but may be useful if applicable). If an
item was indicated as ‘required’ by more than 50 % of
participants in the survey, the item was included in the final
deliberation. Participants were also invited to suggest or
drop items and refine item wording. The second round of
the Delphi panel focused on reviewing all inputs and fi-
nalizing the checklist.
3 Results
After an initial survey invitation and two email reminders,
a total of 16 members of the EuroQol Research Foundation
responded to the survey; 50 % of respondents were female.
Participants came from eight countries in Europe, North
America, and Australia, with 87.5 % working in academia
and 12.5 % in industry.
A total of 22 items were rated as ‘required’ by more than
50 % of survey participants. The consensus on these items
was high. The number of items with a corresponding per-
centage of participants who considered these items as ‘re-
quired’ was 19 by more than 75 % of participants, 17 by
more than 80 % of participants, 11 by more than 90 % of
participants, and 7 by more than 100 % of participants. The
item ‘the attributes and levels of the health states being
valued are described’ was rated as ‘required’ by 80 % of
participants. During deliberation we felt that it might not be
necessary or feasible to report this item in the main text of
the paper, especially for an MAUI with a large number of
possible health states defined. A neighboring item, ‘the
approach to selecting health states to be valued directly is
explained’, could provide sufficient detail to allow for
replicating the health state selection process and then
generating the full list of health states included in the
valuation study. Therefore, we decided that the item ‘the
attributes and levels of the health states being valued are
described’ be dropped from the final list.
The final CREATE consists of a total of 21 items
(Table 1), grouped into seven sections: (1) descriptive
system; (2) health states valued; (3) sampling; (4) prefer-
ence data collection; (5) study sample; (6) modeling; and
(7) scoring algorithm. For each item, a brief explanation for
inclusion of the item is provided, followed by an example.
The examples were selected primarily from those published
valuation studies with a higher score, using the original
version of CREATE [15] or suggestions by the panelists.
Item 1: The Attributes of the Instrument are Described
Explanation
The descriptive system of an MAUI needs to be developed
and validated before a valuation study can be carried out.
‘Attribute’ is used as a general term that is synonymous
with health dimension or domain. The number of attributes
and the content covered by each attribute should be
described.
Example
‘‘The EQ-SD descriptive system consists of 5 dimensions:
mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression’’ [17].
Item 2: The Number of Levels in Each Attribute of the
Instrument is Described
Explanation
To understand the richness of the descriptive system and
issues related to study design, the number of levels in each
attribute should be described, in addition to the description
of each attribute.
Example
The EQ-5D-5L consists of five dimensions, with each di-
mension distinguishing five levels of problems, e.g. no,
slight, moderate, severe, and extreme problems.
Item 3: The Approach to Selecting Health States to be
Valued Directly is Explained
Explanation
Saturation studies, in which all health states described by
an MAUI are valued, are generally not feasible. Therefore,
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a subset of health states needs to be selected for valuation.
The subset of selected health states should be carefully
considered and the selection process described so that the
statistical efficiency and appropriateness of those health
states and implied functional forms can be evaluated.
Example
‘‘The minimum sample of health states for an additive
model was identified using an orthogonal design…which
generated 49 health states (out of 18,000). Alternatively, it
was desirable to value more states to allow for more
complex specifications (allowing for interaction terms). A
stratified sampling method (selecting from health states
categorized as mild, moderate, severe) was used to sup-
plement the 49 states with a further 200 states, to provide
249 health states for valuation’’ [3].
Item 4: The Number of Health States Valued per Re-
spondent is Stated
Explanation
When many health states are selected for valuation, the
respondent burden could become excessive. It is a common
practice that each respondent is required to value a subset
of the selected health states. Therefore, the paper should be
explicit as to how many health states were assigned to each
respondent.
Example
‘‘All stages used a single set of 45 health states, with
each health state described on a separate card. Only 15
health states/cards were used with each respondent’’
[17].
Table 1 CREATE items Item no. Section/item Yes No
Descriptive system
1 The attributes of the instrument are described h h
2 The number of levels in each attribute of the instrument is described h h
Health states valued
3 The approach to selecting health states to be valued directly is explained h h
4 The number of health states valued per respondent is stated h h
5 Method(s) of assigning the health states to respondents are stated h h
Sampling
6 Sample size/power calculations are stated and rationalized h h
7 Target population is described h h
8 Sampling method is stated and rationalized h h
9 Recruitment strategies are described h h
10 Response rate is reported h h
Preference data collection
11 Mode of data collection is stated h h
12 Preference elicitation technique(s) are described h h
Study sample
13 Reasons for excluding any respondents or observations are provided h h
14 Characteristics of respondents included in the analysis are described h h
Modeling
15 The dependent variable for each model is stated h h
16 Independent variables for each model are explained h h
17 Model specifications are provided h h
18 Model estimators are described h h
19 Goodness-of-fit statistics for each model are reported h h
Scoring algorithm
20 Criteria for selecting the preferred model are stated h h
21 The scoring algorithm is presented h h
CREATE Checklist for REporting VAluaTion StudiEs
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Item 5: Method(s) of Assigning the Health States to
Respondents are Stated
Explanation
Further to how many health states were assigned, the
methods used to assign the health states should be de-
scribed so that the concerns regarding framing effects that
may bias the estimates can be mitigated (e.g. randomly
assigned as blocks of health states to each respondent).
Example
‘‘Each respondent was randomly assigned to one of five
groups, which valued 13 health states plus ‘immediate
death’ and ‘unconscious’, as described in Table 1’’ [17].
Item 6: Sample Size/Power Calculations are Stated and
Rationalized
Explanation
Sample size calculations are useful to understand the basis
for the number of respondents and whether or not the study
was adequately powered after study completion.
Example
‘‘Sample size calculations were based on the estimated
number of respondents needed to perform comparisons
among the major racial/ethnic groups in the United States.
These indicated that 4000 completed interviews would be
needed to detect a between-groups difference in mean TTO
valuations of 0.07, with a power of 80 % and probability of
type I error of 0.05. Observed differences between groups
in previous studies suggested that a 7–10 % difference in
valuations was important’’ [17].
Item 7: Target Population is Described
Explanation
It is important to describe the target population from whom
the value set is developed. There are different views on
who is the target population. A popular view is that the
target population is the population that could potentially be
affected by healthcare resource allocation decisions, and
thus is the source of societal preference to inform such
decision making. It is important that researchers and users
of the MAUI find out the view on the target population
adopted by the decision makers in their countries.
Example
‘‘The target population for the study comprised the roughly
210 million civilian noninstitutionalized English- and
Spanish-speaking adults, aged 18 and older, who resided in
the United States (50 states plus the District of Columbia)
in 2002’’ [17].
Item 8: Sampling Method is Stated and Rationalized
Explanation
To develop a value set based on population health prefer-
ence, it is important to recruit a representative sample from
the target population. A proper sampling method is the first
key step to achieving this goal. It determines to what extent
the study sample could represent the target population.
Therefore, a clear and explicit description and justification
of the sampling method are needed.
Example
‘‘A multistage probability sample was selected from the
target population using a sampling frame based on
residential mailing lists and Census demographic data. The
2 largest minority groups in the United States, Hispanics
and non-Hispanic blacks, were oversampled to ensure
adequate numbers of minority respondents’’ [17].
Item 9: Recruitment Strategies are Described
Explanation
Recruitment strategies are aimed at getting a representative
sample, as specified by the sampling method. These
strategies must be clearly described in order to understand
the population basis on which the study sample is recruited
and any potential selection biases which may affect
representativeness.
Example
‘‘In Canada, participants were recruited by random cold
phone call in 2 multi-ethnic cities: Hamilton and Montreal.
English was used as the survey language in Hamilton,
whereas French was used in Montreal’’ [18].
Item 10: Response Rate is Reported
Explanation
Response rate reflects not only feasibility but also gen-
eralizability of the recruitment strategy. A poor response
rate may indicate poor generalizability or study imple-
mentation issues. In contrast, a high response rate sug-
gests that the response generalizes well to the stated target
population. If available, a comparison between respon-
dents and non-respondents in terms of demographics
could also be helpful in further understanding of
generalizability.
Example
‘‘A total of 504 interviews were completed, representing
65 % of eligible respondents who could be contacted (from
an initial random sample of 3000 households in the City of
Hamilton, ON, Canada)’’ [19].
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Item 11: Mode of Data Collection is Stated
Explanation
There are a few modes of data collection that have been
used in MAUI valuation studies. Different modes of data
collection may be associated with not just advantages but
also potential biases, and no data collection method is su-
perior to others. Therefore, it is important to understand
which method was used, and whether quality assurance
was implemented to ensure data quality.
Example
‘‘A trained professional interviewer visited the respondent
in their home. All interviews were audiotape recorded and
a 10 % random sample of interviews were reviewed for
quality control’’ [19]
Item 12: Preference Elicitation Technique(s) are
Described
Explanation
Preference elicitation technique refers to a procedure of
estimating ordinal or cardinal preference for a health state
or multiple health states. There are several commonly em-
ployed preference elicitation techniques, for instance,
matching versus choice-based indifference search proce-
dure [20]. For the same technique there are often variations;
for example, there are several approaches for duration and
routing process presented to respondents in time trade-off
(TTO) [21] and standard gamble choice-based assessments,
and whether there is any imposed boundary in value by
design. Similarly, there are several variants of discrete
choice experiments (DCEs), including forced choice, best-
worst, and inclusion of an immediate death state. These
details should be described to allow for replication.
Example
‘‘Each respondent was instructed to put perfect health at
the top (100) of the FT. Each respondent was then in-
structed to decide which state, the most disabled or dead,
was the least preferred, and place that state at the bottom
(0) of the FT. FT tasks on the left-hand side of the FT
board were completed by rating the most disabled state
or dead, whichever was most preferred, and then the
three marker states. States rated on the left-hand side of
the FT board remained in place during subsequent waves
of ratings on the right-hand side of FT board’’ [19].
Item 13: Reasons for Excluding Any Respondents or
Observations are Provided
Explanation
Health preference elicitation is a complex, cognitively
demanding task. Respondents may not be able to
understand fully the task or the task may be designed in
a way that is difficult to engage respondents. It is
therefore expected that some responses may not meet
predefined criteria and thus are deemed inconsistent.
There is no standard on defining and handling inconsis-
tent responses. Including or excluding inconsistent re-
sponses is also an arbitrary decision and subject to
debate, but needs to be explicitly stated. A sensitivity
analysis of the resulting models to the excluded re-
sponses could also be considered.
Example
‘‘Similar to the MVH and other studies, respondents were
excluded from the valuation sample if all health states were
given the same TTO value or if all health states were
valued worse than death. A number of other criteria were
applied to exclude respondents from the Valuation Sam-
ple’’ [17].
Item 14: Characteristics of Respondents Included in the
Analysis are Described
Explanation
Describing the characteristics of respondents who were
included in the analysis has almost become a standard first
step in reporting any study involving human subjects. It is
especially so in the context where the societal preference
from a representative sample of the general public is a
recommended source of health utility measurement. In
addition, it is recommended to describe the corresponding
characteristics of the general public from which the study
sample is drawn for the purpose of assessing ‘representa-
tiveness’. If any respondents were excluded from the ana-
lysis, it was also recommended to describe the
characteristics of the excluded sample and how they differ
from the included sample.
Example
See the table of characteristics of respondents for the EQ-
5D US valuation study [17].
Item 15: The Dependent Variable for Each Model is
Stated
Explanation
A core step in the data analysis of a valuation study is to
develop a model to predict utilities for all health states
defined by an MAUI from observed utilities of the selected
states. It needs to be explicitly stated what the dependent
variable is in each model. Dependent variables of the
models could take different formats, depending on the
elicitation techniques. For TTO or SG, the elicited utility is
commonly used as the dependent variable in these models.
Notably, there are different ways to present the elicited
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utility; for example, with or without transformation of raw
scores (e.g. for worse than dead states), disutility versus
utility, or decrement from full health or best possible health
state defined by the MAUI. For DCEs, the dependent
variable would be the stated choices.
Example
‘‘Adjusted TTO score h of each health state by each re-
spondent was subtracted from 1, and then these were re-
gressed to 11 dummy variables pertaining to the health
state evaluated’’ [22].
Item 16: Independent Variables for Each Model are
Explained
Explanation
The choice of independent variables can be viewed as an
exercise in search of a reasonable presentation of the de-
scriptive system of an MAUI, in part depending on the
choice of functional form (see Item 17). This is one of the
most challenging parts in the modeling due to the lack of
an agreed theoretical basis on which the descriptive system
should be presented. Unfortunately, this has also become a
neglected part in many valuation studies. Since the first use
of the dummy variables to represent the levels of impair-
ment in the UK EQ-5D valuation study, almost all subse-
quent countries have simply used similar dummy variables
as the core list of independent variables in the modeling.
Despite being intuitive and easily interpretable, this ap-
proach to presenting the MAUI represents only one of
many possibilities and should not be used as the standard.
Researchers are encouraged to explore various ways of
presenting the MAUI’s descriptive system in modeling.
Example
‘‘Where xdl represents ten dummy variables that indicate
the presence of either a level 2 or level 3 in a given di-
mension of the evaluated state. In other words, d stands for
the dimensions: M for mobility, SC for self-care, UA for
usual activities, PD for pain or discomfort, AD for anxiety
or depression; and l stands for either level 2 or level 3.
Since the objective of the exercise is to estimate a function
that maps the five-digit description to average TTO, these
ten xdl dummy variables form the core of the regression’’
[22].
Item 17: Model Specifications are Provided
Explanation
A model specification is a process of selecting an appro-
priate functional form and choosing variables to be in-
cluded. Three major functional forms are additive (used for
the estimation of many EQ-5D scoring algorithms [15] and
SF-6D [3]), multiplicative (used for HUI [2] and the
AQoL-8D [23]), and multi-linear [24]. Once the dependent
and independent variables are defined, there are a number
of possible model specifications. Therefore, it is important
to describe the specification for each model. Often an
equation, supplemented by text description, could be an
efficient and straightforward way of presenting this infor-
mation. If any specification test is used, that should also be
stated.
Example
‘‘Thus, the regression equation is as follows: Y ¼ a þ
b1MO þ b2SC þ b3UA þ b4PD þ b5AD þ b6M2þ
b7S2 þ b8U2 þ b9P2 þ b10A2 þ b11N3 i.e. TTO
scores were explained by 12 independent variables: two
variables for each dimension (one to represent the move
from level 1 to level 2 and one to represent the move from
level 2 to level 3), a term that picks up whether any di-
mension is at level 3, and an intercept’’ [25].
Item 18: Model Estimators are Described
Explanation
Model estimators refer to methods used to estimate the
coefficients of interest, often in a regression model. Dif-
ferent estimators (e.g. ordinary least square, fixed effects,
and random effects) lead to different coefficient estimates.
It is important to explicitly describe the estimators of the
model. Often each respondent is asked to complete the
valuation task for multiple health states. It is important to
explicitly state whether the estimator selection takes ac-
count of repeated measures.
Example
‘‘Since each respondent was expected to have a different
pattern of response, for example, to offer higher or lower
values than the average persistently across all health states,
a random effects (RE) estimation or a fixed effects (FE)
estimation may be used as estimation methods. Therefore,
a series of preliminary analyses was carried out to compare
the simple ordinary least-squares (OLS) regressions with
RE and FE regressions’’ [22].
Item 19: Goodness of Fit Statistics for Each Model are
Reported
Explanation
Goodness of fit is a measure of how well observed data fit a
regression model. Some statistics are commonly used to
measure goodness of fit for regression models; for exam-
ple, the coefficient of determination (commonly denoted
R2), and Akaike Information Criterion. Moreover, it is
important to measure the goodness of fit by assessing the
discrepancy between observed and predicted utilities by the
model since the goal is to predict utilities for all health
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states. Mean absolute error (MAE, or sometimes called
mean absolute difference or mean absolute deviation) is
often used for this purpose. Two approaches aimed at
maximizing external validity of the model prediction are
commonly used to estimate MAEs in valuation studies.
One approach is to split the whole study sample into two
subsamples: one for the model development and the other
for the estimation of MAEs. Another approach is to cal-
culate the MAE by excluding, in turn, each health state
included in the valuation study from the modeling. Since
the goal is to predict utilities of all health states (which
include those not directly included in the valuation), the
second approach is considered a more appropriate indicator
of the predictive ability of a model. A variation on the
second approach is an assessment of the agreement be-
tween directly measured out-of-sample scores (scores not
used to estimate the scoring function for the MAUI) and
scores generated by the scoring algorithm of the MAUI
[19].
Example
‘‘The R2 of 0.46 (in both cases) was very high given the
type of (cross-sectional) data analyzed here,…’’. ‘‘It can be
seen that the predictive power of the model remained high;
only five states had a predicted value that was more than
0.1 different from the actual value, and the mean absolute
difference was again below 0.05. Table 5 shows the pre-
dicted value for each state when direct values for that state
are excluded from the modeling. Only three states had a
predicted value that was more than 0.1 different from its
actual value: the biggest difference was for the most ex-
treme state (ie, 33333), which has a predicted value that is
0.173 below its actual value. The mean absolute difference
was once again below 0.05’’ [25].
Item 20: Criteria for Selecting the Preferred Model are
Stated
Explanation
For any valuation study, an extensive modeling exercise
with different specifications and estimators is always nec-
essary before arriving at a best-performed model for the
value set development. Given multiple indicators could be
used to compare the performance of alternative models, it
is extremely important to describe clearly and explicitly the
criteria used for selecting the best model. Consistency in
predicted utilities between health states (sometimes re-
ferred to as ‘face validity’) is intuitive and commonly used
as the first criterion. In addition, multiple goodness-of-fit
statistics might be available for each model. It is necessary
to state the order in which these criteria are compared. This
description makes the model selection process transparent
and justified.
Example
‘‘To make a choice between different ways of representing
the relationship between the valuations of EuroQol health
states and the different dimensions and levels, the model
that ultimately was chosen had to predict a higher score for
one state, A, than for another, B, if A was logically better
than B on at least one dimension and no worse on any other
dimension. In choosing between the many models that
satisfy this consistency condition, the one that best ex-
plained the differences in the valuations given to those
states on which there was direct data was chosen. For
models with comparable goodness-of-fit statistics, the ul-
timate choice was made according to parsimony, ie, the
simplest model (both in terms of the number of indepen-
dent variables and the ability to explain them) was chosen.
The results presented below are from the ‘‘best’’ model
according to these criteria’’ [25].
Item 21: The Scoring Algorithm is Presented
Explanation
After a comparison between alternative models using pre-
specified criteria, it is very likely that a best-performed
model can be selected. For the model selected as the
scoring algorithm, full details, including coefficient esti-
mates and corresponding standard errors (or 95 % confi-
dence intervals), should be provided. Ideally, the full value
set (i.e. mean prediction and corresponding standard error
or 95 % confidence intervals) derived from this scoring
algorithm is attached to the paper; however, given the
space constraint, especially in peer-reviewed journals, this
may not be feasible. Therefore, it is recommended to
provide an example of how the utility for a health state can
be calculated using the scoring algorithm, accompanied by,
for instance, a website link where the full value set can be
accessed and via different formats (e.g. in SAS, R, or
STATA syntax codes).
Example
‘‘Hence, the predicted value for state 11223 is 1.000-0.000-
0.000-0.140-0.173-0.450-(-0.280)-0.011-0.000-
0.000 = 0.506’’ [17].
4 Discussion
MAUIs have gained widespread popularity in clinical and
economic research [26]. Given their potential impact on
reimbursement decision for new healthcare interventions,
such as innovative but expensive pharmaceuticals, MAUI-
based valuation studies should be reported in a transparent
and adequate manner so that the methodological rigor and
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judgment of the developers can be appraised. The CRE-
ATE is intended to promote good reporting practice and to
guide developers through key elements in study design and
methodology.
Preference-based instruments differ from non-prefer-
ence-based in how they are scored and who the potential
users are. A scoring algorithm for preference-based in-
struments needs to be based on health preferences directly
elicited from the target population, which is much more
complex than the psychometrically-derived scoring for
non-preference-based instruments which typically assume
equal weights across scales and items. Expertise in health
economics, health preference measurement, and econo-
metric modeling is essential to ensure the quality of val-
uation studies. In contrast, healthcare professionals and
policy makers who are users of MAUIs may have little or
no expertise in these fields. The role of MAUIs in health-
care resource allocation decision making implies that the
potential impact of using MAUIs is substantial, albeit im-
plicit, and beyond individual research findings. For exam-
ple, if a value set overestimated average distance between
health states, the incremental cost-effectiveness ratio would
be smaller (thus favoring the intervention under eval-
uation), everything else being equal. This could be trans-
lated into an inefficient use of scarce healthcare resource at
the societal level. Furthermore, there is potential for
gaming of the choice of MAUIs and valuation algorithms
by sponsors seeking reimbursement of new interventions,
and it is important for those involved in evaluating such
decisions to be able to identify any possible sources of bias.
These differences build up barriers to communication,
appraisal, and use of valuation studies among developers
and users and, on the other hand, highlight the need to
enhance the reporting quality for these types of studies.
The CREATE is a methodology-oriented reporting
checklist, due to the characteristics of MAUIs and the
nature of valuation studies. The components of the
checklist are presented in a manner slightly different from
what is commonly seen in other reporting checklists (i.e.
title, introduction, methods, results, and discussion) [27,
28]. Those items typically seen have been either implicitly
embedded in the valuation study itself or covered by other
items in the checklist. For example, the title and objectives
must be clearly presented in order to be considered as an
MAUI valuation study (i.e. to develop a value set for an
instrument for a specific target population). In addition, it is
important to provide sufficient information about the
MAUI itself to allow for a clear understanding of the in-
strument under valuation. Two items under ‘descriptive
system’ cover what and how the introduction section
should be reported. We have elaborated the justification for
this presentation in the discussion. We feel this way of
presentation is more consistent with the order in which
components of MAUI valuation studies are typically
reported.
More recently, there is interest in developing disease-
specific utility-based HRQL instruments [29, 30] or ap-
plying utility-based approaches to existing disease-specific
instruments [31, 32]. This research endeavor probably
arises in response to the criticism of MAUIs lacking suf-
ficient sensitivity in measuring the condition-specific im-
pact on HRQL [33–35]. The CREATE should be
conducive to assessment of the reporting quality of val-
uation studies for disease-specific as well as generic HRQL
instruments.
There are a few limitations with the development of
CREATE. First, there were a relatively small number of
participants in the survey, and all were members of the
EuroQol Group. Nevertheless, research interest, expertise,
and experience of these participants are beyond just the
EQ-5D. Development of CREATE is an ongoing process
and, in future, we plan to involve more researchers outside
the EuroQol Group. Second, we used categorical re-
sponses and arbitrarily chose the majority rule instead of
commonly used ranking and mean scores. The main rea-
son for this consideration was to minimize the impact of
potentially large discrepancies in responses among par-
ticipants which cannot be revealed through a mean score.
Given the high consensus on the final items, the results
would remain the same should we assign a score to each
category and compare the mean scores. Regardless of
which method is used, any threshold may be inevitable
and often arbitrary. Lastly, it is important to note that the
CREATE is developed based on the current theory and
methodology in health preference measures and its appli-
cation in developing a scoring algorithm for MAUIs. Fu-
ture advances in measurement concept and theory may
indicate that an ongoing update on the CREATE is
necessary.
5 Conclusion
The CREATE is aimed at facilitating and promoting
transparent reporting for valuation studies of MAUIs. This
checklist is methodology-oriented and can assist users in
their critical appraisal of value sets and help guide research
related to the design, execution, and reporting of health
valuation studies.
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